Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

US FDA extends review of Exelixis' cancer drug

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pharmalive.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

The US FDA has extended its review of Exelixis' experimental colorectal cancer drug combination, pushing the decision deadline to March 3, 2027, following a major amendment involving updated safety and efficacy data.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must update your market and launch plans as FDA delays add uncertainty to Exelixis’ colorectal cancer drug approval timing. This delay opens a small window for competitors to advance or for you to strengthen your regulatory submissions.

◆ Coverage

1 source · 11 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfdadrug-approvalcancer-drugregulatory-delayexelixis